Log in
Enquire now
‌

Promiliad Biopharma Incorporated STTR Phase II Award, September 2020

A STTR Phase II contract was awarded to Promiliad Biopharma Incorporated in September, 2020 for $751,069.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

AbstractTimelineTable: Further ResourcesReferences
sbir.gov/node/1917175
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
‌
Promiliad Biopharma Incorporated
1
Government Agency
Loading...
1
Government Branch
National Institutes of Health
National Institutes of Health
1
Award Type
STTR1
Contract Number (US Government)
2R42DC017641-02A11
Award Phase
Phase II1
Award Amount (USD)
751,0691
Date Awarded
September 1, 2020
1
End Date
August 31, 2022
1
Abstract

PROJECT SUMMARY Outer ear infections (otitis externa or OE) affect an estimated 10% of people in their lifetime, with associated healthcare costs amounting to over $500 million annually. The pathology is mostly treatable in the general population with topical antibiotics regimes, and can be supplemented in severe cases with systemic counterparts. However, incorrect application or non-compliance with administration schedule of antibiotics leads to infection persistence, recurrence and potentially, development of antibiotic resistant bacterial strains. In diabetic or elderly patients, the infection can be life threatening as it can progress into necrotizing or malignant otitis externa (MOE), with severe health consequences. In recent years, the incidence rate of MOE has seen a significant increase and has been associated with antibiotic resistant bacterial strains. Therefore, there is a critical need to develop safe and effective therapies for the treatment of OE and prevention of MOE. Our approach to this problem is the development of ThixOtic, a proprietary drug delivery system that would enable the one-time point-of-care application of drugs to effectively treat the infection and diminish treatment non-compliance related risk of antibiotic resistance development, infection recurrence and complications.PROJECT NARRATIVE We seek to continue the advancement to commercialization of our proprietary drug delivery system ThixOtic. The work proposed will result in the technology transfer readiness of this technology for applications such as antibiotic delivery system for the treatment of otitis externa.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Promiliad Biopharma Incorporated STTR Phase II Award, September 2020

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.